Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasisReportar como inadecuado

Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Hematology and Oncology

, 10:28

First Online: 21 January 2017Received: 24 July 2016Accepted: 30 December 2016DOI: 10.1186-s13045-016-0383-x

Cite this article as: Na, H., Liu, X., Li, X. et al. J Hematol Oncol 2017 10: 28. doi:10.1186-s13045-016-0383-x


BackgroundTumor metastasis is an essential cause of the poor prognosis of colon cancer. DC-SIGNR is a C-type lectin that is frequently found on human liver sinusoidal endothelial cells. LSECtin, which is a homologue of DC-SIGNR, has been demonstrated to participate in colon cancer liver metastasis. Due to the similarities in the expression pattern and structure of the two proteins, we speculated that DC-SIGNR could also be involved in this process.

MethodsColon cancer cells were treated with the DC-SIGNR protein or control IgG, after which cell migration, invasion, and morphology were assayed. Xenograft mouse models were used to determine the role of DC-SIGNR in colon cancer liver metastasis in vivo. In addition, a human gene expression array was used to detect differential gene expression in colon cancer cells stimulated with the DC-SIGNR protein. The serum level of DC-SIGNR was examined in colon cancer patients by ELISA, and the significance of DC-SIGNR was determined.

ResultsIn our research, we investigated whether DC-SIGNR promotes colon cancer cell adhesion, migration, and invasion. Knocking down mouse DC-SIGNR decreased the liver metastatic potency of colon cancer cells and increased survival time. Expressing human DC-SIGNR enhanced colon cancer liver metastasis. Furthermore, DC-SIGNR conferred metastatic capability on cancer cells by upregulating various metallothionein isoforms. To validate the above results, we also found that the serum DC-SIGNR level was statistically higher in colon cancer patients with liver metastasis compared with those without metastasis.

ConclusionsThese results imply that DC-SIGNR may promote colon carcinoma hepatic metastasis and could serve as a promising therapeutic target for anticancer treatment.

KeywordsDC-SIGNR Colon cancer liver metastasis Metallothioneins AbbreviationGAPDHGlyceraldehyde-3-phosphate dehydrogenase



PBSPhosphate-buffered saline

Electronic supplementary materialThe online version of this article doi:10.1186-s13045-016-0383-x contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Heya Na - Xiaoli Liu - Xiaomeng Li - Xinsheng Zhang - Yu Wang - Zhaohui Wang - Menglang Yuan - Yu Zhang - Shuangyi Ren -


Documentos relacionados